CliffBio
small molecule

BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

Loss of exclusivity—loss of exclusivity
CompanyTeva →See this company's full patent-cliff portfolio

Drug detail

Brand nameBUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE
Active ingredientBUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE
Strength0.16MG/INH;0.0045MG/INH
Dosage formAEROSOL, METERED
RouteINHALATION
ModalitySmall molecule
FDA approvalApril 2026
Marketing statusRX

More from Teva

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE patent cliff — loss of exclusivity — | CliffBio